LRMR
Larimar Therapeutics Inc

4,523
Mkt Cap
$337.23M
Volume
340,519.00
52W High
$6.48
52W Low
$1.61
PE Ratio
-2.04
LRMR Fundamentals
Price
$4.05
Prev Close
$3.94
Open
$4.01
50D MA
$3.90
Beta
1.37
Avg. Volume
1.63M
EPS (Annual)
-$1.32
P/B
2.43
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
FY2025 Earnings Forecast for LRMR Issued By Leerink Partnrs
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Larimar Therapeutics in a report issued on...
MarketBeat·1mo ago
News Placeholder
Equities Analysts Issue Forecasts for LRMR FY2025 Earnings
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research report...
MarketBeat·1mo ago
News Placeholder
William Blair Has Negative Forecast for LRMR FY2025 Earnings
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at William Blair cut their FY2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research report...
MarketBeat·1mo ago
News Placeholder
FY2029 EPS Estimates for Larimar Therapeutics Cut by Wedbush
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Stock analysts at Wedbush dropped their FY2029 earnings estimates for shares of Larimar Therapeutics in a note issued to investors on...
MarketBeat·1mo ago
News Placeholder
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Misses Estimates By $0.22 EPS
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·1mo ago
News Placeholder
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation LRMR
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from...
Business Wire·1mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1mo ago
News Placeholder
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation LRMR
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from...
Business Wire·2mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2mo ago

Latest LRMR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.